ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/d5504f9bf5473db2c0312f561b1dd2c3.pdf

Abstract Title *

ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Hiddo J.L. Heerspink h.j.lambers.heerspink@umcg.nl University of Groningen, University Medical Center Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands -

Co-author 2

Daniel H. van Raalte d.vanraalte@amsterdamumc.nl Amsterdam University Medical Center Diabetes Center, Department of Internal Medicine Amsterdam Netherlands -

Co-author 3

Katherine Tuttle Katherine.tuttle@providence.org Providence Inland Northwest Health and University of Washington School of Medicine Providence Medical Research Center Spokane United States -

Co-author 4

David Z.I. Cherney David.Cherney@uhn.ca Toronto General Hospital, University of Toronto Department of Medicine Toronto Canada -

Co-author 5

Petter Bjornstad pettermb@uw.edu University of Washington School of Medicine University of Washington Medicine Diabetes Institute Seattle United States -

Co-author 6

Carolina Piras De Oliveira carolpiras@icloud.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 7

Georgios K. Dimitriadis georgios.dimitriadis@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 8

Dachuang Cao cao_dachuang@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 9

Bruno Linetzky linetzky_bruno@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 10

Irina Jouravskaya jouravskaya_irina@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 11

Ryan Griffin ryan.griffin@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -

Co-author 12

Yusuke Takahashi (non-author presenter) takahashi_yusuke@lilly.com Eli Lilly Japan K.K. Japan Drug Development and Medical Affairs Kobe Japan *

Co-author 13

Co-author 14

Co-author 15

Introduction

Obesity and type 2 diabetes (T2D) lead to kidney damage and decline in function over time. Tirzepatide (TZP) has been associated with kidney protective effects in people with T2D and with improvements in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) in people with obesity or overweight after 72 weeks of treatment. The current analysis aimed to determine if improvements in kidney parameters persist over 176 weeks of TZP treatment in people with obesity and prediabetes.

Methods

SURMOUNT-1 was a 72-week, randomized Phase 3 study to evaluate the effects of TZP (5 mg, 10 mg, 15 mg) versus placebo in participants with obesity (BMI≥30 kg/m2) or overweight (BMI≥27 kg/m2) with weight-related comorbidities (excluding T2D) (NCT04184622). In the current post-hoc analysis, participants with prediabetes at randomization underwent an additional 104-week treatment follow-up period. UACR and eGFR (CKD-EPI Creatinine-Cystatin Equation 2021) were assessed for TZP (pooled 5/10/15 mg; n=762) or placebo (n=270). Change from baseline to week 176 was analyzed using mixed models for repeated measures with on-treatment data.

Results

Baseline mean eGFR was 97.1±17.6 ml/min per 1.73m2 and median UACR was 7.0 mg/g (interquartile range 4.0 – 12.0 mg/g). A significantly smaller decline in eGFR was observed with pooled TZP (-1.6±0.5 ml/min per 1.73m2) compared to placebo (-5.5±1.0 ml/min per 1.73m2) after 176 weeks (estimated treatment difference (ETD) of 3.9 ml/min per 1.73m2, p<0.001). A greater percentage decrease in UACR was observed with pooled TZP (-15.8±2.9%) compared to placebo (-3.9±6.4%) after 176 weeks (ETD of -12.4%, p=0.078).

Conclusion

In SURMOUNT-1 participants with prediabetes, overweight or obesity, and preserved eGFR at baseline, use of TZP was associated with an attenuated decline of eGFR over 3 years with a nonsignificant trend toward UACR reduction.

This abstract was also submitted for the American Diabetes Association – 85th Annual Scientific Sessions, Chicago, IL, USA, in 2025.

Kewords